

FDA RESPONSE:

The modified _____ method is acceptable as long as it provides needed resolution of all the impurities above 0.1% and the impurities are identified. The Division asked to submit an IND amendment for the new _____ method and to make sure that the method is stability indicating.

2. Cubist plans to modify the existing manufacturing process for bulk daptomycin currently being used by _____ to produce clinical supplies. These changes have been outlined in the meeting package and will be submitted as an IND amendment. **Does FDA agree that the proposed comparability testing for bulk daptomycin and daptomycin drug product outlined in the meeting package is adequate to qualify material produced by the modified manufacturing process thereby allowing the material to be used in the Phase 3 clinical trials?**

FDA RESPONSE:

The comparability protocol for _____ versus _____ appears to be acceptable, but the acceptance criteria for the sameness should be provided and justified. In addition, the impurity profiles of the drug substance before and after the change should be included.

3. Due to limitations for purification capacity at _____, Cubist needs to manufacture bulk daptomycin at _____ for commercial manufacturing. _____ process will be submitted in the NDA as the sole manufacturer of bulk daptomycin. **Is the comparability testing between the bulk material produced at _____ and _____ adequate to support an NDA? Is the comparability testing of the daptomycin drug product produced using material produced at _____ and _____ adequate to support an NDA?**

FDA RESPONSE:

The plan for bridging studies for the change in the manufacturing site from _____ to _____ acceptable for submission in the NDA. The division's understanding is that _____ material will not be used in the clinical studies for NDA submission. The data and acceptance criteria will be reviewed to determine acceptance of the drug substance from the new site. Also, the data for the drug product manufactured from the new source of the drug substance will be reviewed in the NDA.

4. Primary drug product stability data for the NDA will be generated using bulk daptomycin produced at _____ and drug product produced by the commercial drug product manufacturer (either Abbott _____). Please be aware that the manufacturing procedures to produce bulk drug are essentially the

same between _____ and the commercial supplier _____. Is the proposed approach of using _____ bulk drug for primary drug product stability studies acceptable providing the equivalence between bulk material produced by _____ and _____ is established?

FDA RESPONSE:

Primary drug product stability data for the NDA will be acceptable if comparability is demonstrated between the drug substance batches manufactured at _____ (clinical site) and at _____ (proposed commercial site).

5. Abbott will produce _____ daptomycin vials in _____ with varying capacities. For the primary stability studies, _____ will operate at _____ capacity. Does the FDA agree with the proposed primary stability plan outlined in the meeting package?

FDA RESPONSE:

This is acceptable.

6. Since daptomycin is produced using a _____ process, the firm claims that FDA guidelines permit identification of impurities which occur at 0.3% or greater. Cubist plans to identify any impurity in the bulk daptomycin that is present at this level. Is this acceptable to the FDA?

FDA RESPONSE:

The acceptance criteria of 0.3% limit referenced in the "Guide for Inspection on Fermentation of Bulk Drug Substance" are contingent on review of the impurity profile data and methods for optimized process.

Agreements: See discussion/recommendation section

Issues Requiring Further Discussion: See discussion/recommendation section

Enclosure: None

Action Items: None

Minutes Preparer: Jose R. Cintron, R.Ph., M.A.
Senior Regulatory Management Officer

Chairs Concurrence: Dr. Chi Wan Chen,
Office Director, DNDC-III

This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.

/s/

Chi Wan Chen
7/24/02 02:50:26 PM

MEMORANDUM OF TELECON

DATE: April 29, 2003 TIME: 1:15 PM LOCATION: S-348

APPLICATION NUMBER: NDA 21-572

DRUG NAME: CIDEKIN[®] (daptomycin for injection)

BETWEEN:

Name:

David Schubert
Judy Newberne

Vice President, Regulatory Affairs and Quality
Director, Regulatory Affairs

Representing: Cubist Pharmaceuticals, Inc.

AND

Name:

Janice Soreth, MD	Director, DAIDP
David Ross, MD, PhD	Medical Team Leader
Susan Thompson, MD	Medical Officer
Sumathi Nambiar, MD, MPH	Medical Officer
LT Daniel Nguyen, RPh	Regulatory Health Project Manager

Representing: Division of Anti-Infective Drug Products, HFD-520

BACKGROUND:

On April 10, 2003 the Division informed the sponsor of the discrepancies in the data sets for study 9801. The Division emphasized the importance of resolving these discrepancies. This teleconference was held to further discuss action plans in addressing the discrepancies within the data sets.

MEETING OBJECTIVE(S):

To clarify action plans in resolving data set issues discovered by the Division.

DISCUSSION AND RECOMMENDATIONS:

The sponsor conveyed the following to the Division:

1. The sponsor will provide a written response outlining their understanding of the problem with the data sets.
2. The sponsor will inform the Division of which data sets are involved.
3. The sponsor will explain how the individual data sets, and ISS and ISE data sets were derived.
4. The sponsor will provide a time frame for submission of corrected data sets.

ACTION ITEMS:

- The sponsor will comply with the requests within the Discussion and Recommendation section after consulting with the contractor who constructed the data sets.
- Further discussion of data set issues will be addressed in a face-to-face meeting to be arranged between the sponsor and the Agency.



LT Daniel Nguyen, RPh
Regulatory Health Project Manager
Minutes Recorder



David Ross, MD, PhD
Medical Team Leader

==

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.